top of page
KRAS Cancer News & Updates
PROSPER trial for KRAS G12C mutations
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER) Phase 1/2 - 403 patients to enroll Opened in...
fireflyannf
Apr 7, 2025
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
"This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK),...
fireflyannf
Apr 7, 2025
Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS
Phase 1 trial Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumors Enrollment into...
fireflyannf
Apr 7, 2025
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
"Brief Summary Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as...
fireflyannf
Apr 7, 2025
BREAKER-101 trial - Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors
“First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in...
fireflyannf
Apr 7, 2025
Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic, colorectal and non-small cell lung cancer
ESMO24 abstract 608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in...
fireflyannf
Mar 30, 2025
KICKING KRAS LUNG CANCER!
Upstage Lung Cancer heard the power of hope to kick cancer from Terri Conneran
Terri Conneran KRAS Kickers
Dec 19, 2024
SPARK study: Studying Pathways of Resistance in KRAS-12C driven Cancers
Brief Summary “Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally...
fireflyannf
Oct 13, 2024
Revolution Medicines: RMC-6236 Pancreatic Cancer Update to Support Pivotal Phase 3 Trial
Rev Med reports out on the 46% of the pancreatic cancer patients who were enrolled in NCT05379985 (54% of patients are NSLC or other...
fireflyannf
Jul 24, 2024
Honoring Jerry Cornelius of Canyon Creek. Family Man, Texan, Craftsman
https://www.kraskickers.org/post/honoring-jerry-cornelius-of-canyon-creek-family-man-texan-craftsman
Cancer Treatment & Clinical Trial Eligibility: What Patients Need to Know
Once you know your options, the next question is: Am I eligible? Here’s how doctors typically determine if a patient qualifies for a clinical trial or specific therapy—regardless of cancer type.
6 things that matter...
What Every Cancer Patient Should Know About Today’s Treatment Options
..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.
bottom of page